OphthalmoPharma Ltd.
http://www.ophthalmopharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From OphthalmoPharma Ltd.
Start-Up Quarterly Statistics, Q3 2011
Biopharma start-ups raised $299 million and just over half were Series A rounds. Device companies brought in $134 million, while two diagnostics firms raised $10 million total. Ophthalmology was the most popular theracat for biopharma alliances. Just one acquisition involving a start-up took place.
Altacor to evaluate lead compound from Proximagen's 5HT2c programme for glaucoma
The UK specialty ophthalmic pharma company, Altacor Limited, has entered into a collaborative agreement with Proximagen to research and develop PRX00933 – the lead compound from Proximagen's 5HT2c programme acquired as part of the acquisition of Cambridge Biotechnology – as a treatment for glaucoma. Altacor also has the option for exclusive, global rights to develop the candidate in all ophthalmic indications.
Deals Shaping the Medical Industry (09/2011)
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
Company Information
- Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice